These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Interaction of the v-Rel oncoprotein with NF-kappaB and IkappaB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo. White DW, Pitoc GA, Gilmore TD. Mol Cell Biol; 1996 Mar; 16(3):1169-78. PubMed ID: 8622661 [Abstract] [Full Text] [Related]
4. The Rel family: models for transcriptional regulation and oncogenic transformation. Bose HR. Biochim Biophys Acta; 1992 Sep 14; 1114(1):1-17. PubMed ID: 1327144 [No Abstract] [Full Text] [Related]
5. Oncogenic transformation by vrel requires an amino-terminal activation domain. Kamens J, Richardson P, Mosialos G, Brent R, Gilmore T. Mol Cell Biol; 1990 Jun 14; 10(6):2840-7. PubMed ID: 2111443 [Abstract] [Full Text] [Related]
6. Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts. Morrison LE, Boehmelt G, Enrietto PJ. Oncogene; 1992 Jun 14; 7(6):1137-47. PubMed ID: 1594245 [Abstract] [Full Text] [Related]
7. Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein. Chen C, Agnès F, Gélinas C. Mol Cell Biol; 1999 Jan 14; 19(1):307-16. PubMed ID: 9858554 [Abstract] [Full Text] [Related]
8. A protein kinase-A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel. Mosialos G, Hamer P, Capobianco AJ, Laursen RA, Gilmore TD. Mol Cell Biol; 1991 Dec 14; 11(12):5867-77. PubMed ID: 1944267 [Abstract] [Full Text] [Related]
9. Molecular mechanisms of transformation by the v-rel oncogene. Hannink M, Temin HM. Crit Rev Oncog; 1991 Dec 14; 2(4):293-309. PubMed ID: 1958712 [Abstract] [Full Text] [Related]
10. Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T. Bhat GV, Temin HM. Oncogene; 1990 May 14; 5(5):625-34. PubMed ID: 2189101 [Abstract] [Full Text] [Related]
15. The N-terminal env-derived amino acids of v-rel are required for full transforming activity. Garson K, Percival H, Kang CY. Virology; 1990 Jul 14; 177(1):106-15. PubMed ID: 2162102 [Abstract] [Full Text] [Related]
16. A mutant v-rel with increased ability to transform B lymphocytes. Romero P, Humphries EH. J Virol; 1995 Jan 14; 69(1):301-7. PubMed ID: 7983722 [Abstract] [Full Text] [Related]
17. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. Carrasco D, Rizzo CA, Dorfman K, Bravo R. EMBO J; 1996 Jul 15; 15(14):3640-50. PubMed ID: 8670867 [Abstract] [Full Text] [Related]
18. Expression of v-rel in a replication competent virus: transformation and biochemical characterization. Morrison LE, Boehmelt G, Beug H, Enrietto PJ. Oncogene; 1991 Sep 15; 6(9):1657-66. PubMed ID: 1656369 [Abstract] [Full Text] [Related]
19. Analysis of the role of v-rel in transcriptional regulation of high mobility group 14. Walker AK, Enrietto PJ. Oncogene; 1996 Jun 20; 12(12):2515-25. PubMed ID: 8700510 [Abstract] [Full Text] [Related]
20. A similar DNA-binding motif in NFAT family proteins and the Rel homology region. Jain J, Burgeon E, Badalian TM, Hogan PG, Rao A. J Biol Chem; 1995 Feb 24; 270(8):4138-45. PubMed ID: 7876165 [Abstract] [Full Text] [Related] Page: [Next] [New Search]